Nxera Pharma Seeks South Korean Approval for Insomnia Drug Daridorexant
Event summary
- Nxera Pharma submitted a marketing authorization application for daridorexant in South Korea on March 4, 2026.
- The Phase 3 trial in South Korea met primary and secondary efficacy endpoints for insomnia treatment.
- Daridorexant is already approved and marketed in Japan as QUVIVIQ® under a partnership with Shionogi.
- Insomnia affects 15-25% of South Korea's adult population, or 6.5-11 million people.
The big picture
Nxera Pharma's submission for daridorexant in South Korea marks a strategic push into a high-prevalence insomnia market. With the drug already approved in Japan and clinical trials showing positive results, Nxera is positioning itself as a key player in the dual orexin receptor antagonist space. The move comes as insomnia rates rise, particularly among older adults and women in South Korea, highlighting a significant unmet medical need.
What we're watching
- Regulatory Timeline
- Whether the MFDS will approve daridorexant by the anticipated 2027 deadline.
- Market Penetration
- How Nxera Pharma will position daridorexant against existing insomnia treatments in South Korea.
- Commercial Strategy
- The pace at which Nxera can expand daridorexant's reach beyond Japan and South Korea.
Related topics